Key result
Five SNPs within the ADORA2a gene were significantly associated with stopping methotrexate for adverse events, specifically gastrointestinal toxicity (OR 2.1-3.07, P < 0.05).
Why the study?
Are ADORA2a gene polymorphisms associated with adverse events or inefficacy in RA patients treated with MTX?
Case-Control (n=309)
Are ADORA2a gene polymorphisms associated with adverse events or inefficacy in RA patients treated with MTX?
Effect estimate: OR 2.1-3.07
p-value: p=< 0.05
Genetic variation within the ADORA2a gene is significantly associated with gastrointestinal adverse events in rheumatoid arthritis patients treated with methotrexate, which may help identify high-risk patients.
OBJECTIVE: To examine the role of adenosine receptor 2a gene (ADORA2a) polymorphisms on outcome of MTX treatment in RA. METHODS: Subjects included 309 RA patients with a defined response to MTX. Patients were included if they were (i) good responders (n = 147) (ESR <20 for >6/12 on stable dose of MTX) (ii) inefficacy failures (n = 101) (physician statement and failure to reduce ESR/CRP by 20%) or (iii) adverse event (AE) failures (n = 61) (verified by medical record review). AEs were sub-divided into gastrointestinal (GI) (n = 24), abnormal LFTs (n = 20) or other (n = 17). 8 single nucleotide polymorphisms (SNPs) within ADORA2a were genotyped using the Sequenom MALDI-TOF platform. RESULTS: Five SNPs within ADORA2a were associated with stopping MTX for AEs (OR 2.1-3.07, P < 0.05 for all). Analysis by AE type showed that the association was specific for GI toxicity. No association was observed between ADORA2a and inefficacy outcomes. CONCLUSION: Genetic variation within ADORA2a is significantly associated with AEs on MTX, specifically GI AEs. Knowledge of the ADORA2a genotype may help to improve identification of patients at high risk of GI toxicity with MTX.
No takes yet. Share an insight, caveat, or question.
Hider et al. (2008) conducted a case-control in Rheumatoid Arthritis (n=309). ADORA2a gene polymorphisms vs. Reference genotypes was evaluated on Stopping MTX for adverse events (OR 2.1-3.07, p=< 0.05). Five SNPs within the ADORA2a gene were significantly associated with stopping methotrexate for adverse events, specifically gastrointestinal toxicity (OR 2.1-3.07, P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: